title: High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - Commentary.
authors.affiliation: MS Center Amsterdam, VU University Medical Center Amsterdam, Amsterdam, The Netherlands/Departments of Radiology and Nuclear Medicine, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
authors.forename: Mike P
authors.initials: MP
authors.lastname: Wattjes
authors.affiliation: Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
authors.forename: Clemens
authors.initials: C
authors.lastname: Warnke
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal; D008279:Magnetic Resonance Imaging; D000069442:Natalizumab; D012306:Risk
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab